Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Psychedelic Drug Trials, Patient Safety Take Spotlight at FDA Hearing

16 September 2026 · By · Wire by Fusion42

Published

16 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at medpagetoday.com →

◆ Verified

Fusion42 · 17 September 2026 · Fusion42 review

The FDA held a public hearing focusing on safety and regulatory considerations for psychedelic drug trials targeting severe mental illness. Stakeholders discussed trial oversight and patient safety measures amid growing interest in therapeutic psychedelics.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 14 Sep 2026 and 16 Sep 2026.

◆ ◆ The Wire takeaway

You face tighter scrutiny on patient safety if your biotech company works with psychedelic therapies. This FDA focus means your next trial must prioritise robust oversight to clear regulatory hurdles.

◆ Coverage

4 sources · first reported 14 Sep 2026 · latest 16 Sep 2026

◆ Related on Wire

◆ Topics

BiotechpsychedelicsFDAdrug-trialspatient-safetyregulation